Taconic Biosciences
Taconic Biosciences, a leading provider of genetically engineered rodent models, is headquartered in the United States, with significant operations across Europe and Asia. Founded in 2007, the company has established itself as a key player in the biotechnology industry, focusing on preclinical research and model development for drug discovery and development. Taconic's core offerings include custom mouse models, biorepositories, and advanced breeding services, all designed to meet the specific needs of researchers in academia and the pharmaceutical sector. What sets Taconic apart is its commitment to quality and innovation, ensuring that their models are not only reliable but also tailored to the unique requirements of each project. With a strong market position, Taconic Biosciences has achieved notable milestones, including partnerships with leading pharmaceutical companies and contributions to significant scientific advancements. Their dedication to excellence continues to drive their reputation as a trusted resource in the field of biomedical research.
DitchCarbon Score
How does Taconic Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Taconic Biosciences's score of 3 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Taconic Biosciences's reported carbon emissions
Taconic Biosciences, headquartered in the United States, currently does not have publicly available carbon emissions data for the most recent year. However, the company has made significant commitments towards reducing its carbon footprint. Taconic is committed to near-term reduction targets, although specific numerical targets have not been disclosed. As of December 2023, Taconic has not committed to a net-zero target, indicating a focus on immediate emissions reductions rather than long-term climate neutrality. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector, which is increasingly under pressure to address climate change and reduce greenhouse gas emissions. While specific emissions data is lacking, Taconic's commitment to near-term reduction targets reflects an awareness of the importance of sustainability in their industry. The absence of detailed emissions figures highlights a common challenge in the sector, where many companies are still in the early stages of formalising their climate strategies.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Taconic Biosciences is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
